Asia

With over 20 years of life sciences experience spanning VC, entrepreneurship and research, Dr. Wang has co-founded OrbiMed Asia. Previously, he was a Partner at Legend Capital and General Manager at Burrill Greater China Group. He also worked for WI Harper as a Managing Director, and Walden International. He was a Board Director at ForteBio and is a Board Director at EA, Inc., Response Biomedical Corporation and Bonovo Orthopedics. He is a co-founder and former Chairman of BayHelix, a premier group of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he conducted research with of Eric Kandel, a Nobel Laureate. He received the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.

Dr. Sunny Sharma is a Senior Managing Director on the Asia team. Prior to joining OrbiMed, Dr. Sharma was with Investor Growth Capital (IGC), the wholly owned global venture capital arm of Investor AB, and before that with Easton Capital in New York. Earlier in his career, Dr. Sharma worked in the healthcare investment banking group of Lehman Brothers in London, and before that he practiced medicine in northern India. Dr. Sharma holds an M.B.A. from the Indian Institute of Management, Bangalore and a medical degree (M.B.B.S.) from Christian Medical College, Ludhiana where he was awarded the Vipin Khanna Memorial Gold Medal for graduating as the best intern.

Dr. David Wang is a Senior Managing Director, Asia. Most recently, he was a Managing Director at WI Harper Group, responsible for healthcare investment in China. Previously, he served as Head of Business Development at Siemens Medical Solutions, where he directed corporate strategy and new businesses in molecular diagnostics and diagnostic imaging. He was co-founder and EVP at First Genetic Trust, a personalized medicine company. During his tenure at Bristol-Myers Squibb, he was Chairman of The SNP Consortium Management Committee, the first group of its kind formed by pharmaceutical and technology industries to support the development of personalized medicine. He received his MD from Peking University Medical School. He earned his doctorate in Developmental Biology from California Institute of Technology.

Rajesh Dalal is a Venture Partner on the Asia team. Prior to joining OrbiMed, Mr. Dalal spent more than 30 years with Johnson and Johnson (J&J) in Asia including the past five years as the head of M&A for J&J Medical in the Asia Pacific Region. In this role, he worked closely with scores of medical device companies in China, India and other parts of Asia. Mr. Dalal was previously the Managing Director of J&J Medical, India for six years with overall responsibility for the medical device businesses at Cordis, DePuy, Endo, Lifescan, Ethicon and Hospital Supplies. A native of Mumbai, Mr. Dalal is a mechanical engineer from the prestigious IIT Madras, and holds an M.B.A. from Bajaj Institute, Bombay. 

Dr. Hongbo Lu is an Executive Director on the Asia team. Previously, Dr. Lu spent more than five years at Piper Jaffray & Co as an equity analyst. She led Piper's China healthcare research team and was instrumental in building the firm's brand in the Asian marketplace. Prior to her Wall Street career, Dr. Lu spent four years in life science start-up operations and business development at Zyomyx, Inc. Dr. Lu received a Ph.D. in BioEngineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and a B.S./M.S. in Materials Science and Engineering from Tsinghua University in China.

Daniel Zhou is a Vice President on the Asia team. Prior to joining OrbiMed, he worked as a Vice President at WI Harper Group where he was responsible for healthcare investments in China. Previously, he was an Assistant Vice President at Balloch Group, helping Chinese medical companies to obtain financing from private equity firms.  He also previously worked on the Transaction Service team at PwC Beijing Advisory, responsible for the financial due diligence of various investment opportunities. He received his master's degree in Finance from Renming University of China, and holds a certificate of Certified Public Accountant in China.

Swati Bansal is a Senior Associate on the Asia team. Prior to joining OrbiMed, she worked as a Global Healthcare Analyst in the proprietary equity division at DSP Merrill Lynch in Mumbai, and was responsible for spearheading a portfolio of Asian healthcare stocks. Previously, Swati was a Senior Analyst at Genpact where she earned the prestigious Silver Award in 2007, and before that she started her career as a Research Analyst at Irevna Research, a Standard & Poors' company. Swati received her CFA Charter and M.B.A. from ICFAI University, Hyderabad. She also holds an Engineering degree (B.E.) in Medical Electronics from BMS College of Engineering, Bangalore. 

Dr. Vikram Popli is a Senior Associate on the Asia team. Prior to joining OrbiMed, he worked as a Senior Business Analyst with Bristol Myers Squibb in Mumbai where he was responsible for diligence and financial analysis of various business development opportunities. Dr. Popli graduated from the prestigious Maulana Azad Medical College in Delhi and specialized in Orthopedic Surgery at Safdarjang Hospital. He also has an MBA in finance from the Indian School of Business, Hyderabad.

Clive Wang is an Associate on the Asia team. Prior to joining OrbiMed, Mr. Wang worked at IDG Capital Partners and McKinsey & Company. His deal coverage has included Pharmaceuticals, Biologics, Medical Devices, Healthcare Services, and Healthcare IT. Mr. Wang received an M.S. in Statistics from University of Chicago, a master's degree in Molecular Pharmacology and Experimental Therapeutics from Mayo Graduate School of Mayo Clinic, and a B.S. in Biology from Fudan University.